NCT03256136View on ClinicalTrials.gov

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 22, 2017

Primary Completion Date

August 19, 2019

Study Completion Date

August 19, 2019

Conditions
Lung Cancer
Interventions
DRUG

Carboplatin

Chemotherapy

DRUG

Nivolumab

will allow the body's immune system to work against tumor cells

DRUG

pemetrexed

Chemo therapy

DRUG

Ipilimumab

will allow the body's immune system to work against tumor cells

Trial Locations (3)

02115

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

02214

Massachusetts general Hospital, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Massachusetts General Hospital

OTHER